Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Recruiting 2Completed 2Unknown 1

Sponsor Class

OTHER 6INDUSTRY 5OTHER_GOV 1

Study Type

Interventional 5

Sponsor

Cancer Type

Other solid neoplasm 98Breast 47Thoracic 43Gastrointestinal 42Genitourinary 23Lymphoid 21Gynecologic 21Head & Neck 17Other hematologic neoplasm 12Plasma cell 11Tumor-Agnostic 10Dermatologic 9Sarcoma 7Endocrine 5Myeloid 4CNS 4Other 3NET 2Classical hematology 2Other neoplasm 1

Conditions

Differentiated Thyroid Cancer 2Tuberous Sclerosis 1Thyroid Cancer, Papillary 1Neuroendocrine Tumors 1Gastroenteropancreatic Neuroendocrine Tumors 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Adenocarcinoma, Follicular 1

Interventions

Everolimus 23pasireotide 14lutetium Lu 177 dotatate 10Octreotide 10lanreotide 9surufatinib 8Carboplatin 8Paclitaxel 7pembrolizumab 5amino-acid, glucose, and electrolyte solution 5Thyrotropin Alfa 5Sunitinib 5Nivolumab 5Injections 53-Iodobenzylguanidine 5relacorilant 4fosbretabulin 4Temozolomide 4Fulvestrant 4Etoposide 4Data Collection 4Cisplatin 4vandetanib 3selpercatinib 3dabrafenib 3anlotinib 3Mifepristone 3Lutetium-177 3Lutetium 3Irinotecan 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × Injections × Endocrine × Clear all
NCT07165886 2026-04-24

Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 2/3 Recruiting
298 enrolled
EndocrineGastrointestinalNET

Gastroenteropancreatic Neuroendocrine Tumors

NCT07369505 2026-01-27

Sapu003 in Advanced mTOR-sensitive Solid Tumors

SAPU NANO (US) LLC

Phase 1 Recruiting
27 enrolled
EndocrineGastrointestinalGenitourinaryNET

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Tuberous Sclerosis, Neuroendocrine Tumors

NCT04137185 2024-03-06

Clinical Trial of Dose-tolerance, Pharmacokinetics and Iodine Uptake For rhTSH In Post-thyroidectomized Patients

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 1/2 Completed
64 enrolled
EndocrineHead & Neck

Differentiated Thyroid Cancer

NCT04447183 2023-10-23

DTC

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 2 Unknown
120 enrolled
EndocrineHead & Neck

Differentiated Thyroid Cancer

NCT00295763 2015-03-18

A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen.

Sanofi

Phase 3 Completed
61 enrolled
EndocrineHead & Neck

Thyroid Cancer, Papillary, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡